Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections.
Auris Nasus Larynx. 2012 Oct; 39(5):512-8.AN

Abstract

OBJECTIVE

To determine the efficacy and safety of garenoxacin, a new generation of quinolone antimicrobial agent, in the treatment of adult upper respiratory tract infections.

METHODS

A total of 113 subjects were enrolled in this study. Garenoxacin (400mg/day) was administered to patients with pharyngolaryngitis, tonsillitis, and otitis media for 5-7 days and to those with sinusitis for 7-10 days. Clinical symptoms and findings were examined and quantitatively evaluated using a scoring system.

RESULTS

We found 80 to 100% improvement rate in symptoms and findings for each infection. In addition, we found significant improvement in subjective evaluations from patient questionnaires even in the early stage of the treatment. X-ray examination for acute sinusitis demonstrated that the clinical efficacy was 84% (27/32) and 76% (19/25) patients were already improved within seven days. Among the detected 84 bacteria, 75 (89%) were identified as the major pathogenic bacteria of respiratory tract infections such as Streptococcus pneumoniae (27 strains) and Haemophillus influenzae (14 strains). Garenoxacin administration completely eradicated bacteria in 53 out of 54 cases (98%). There were 8 adverse events (8.3%) including 3 diarrhea cases (3.1%).

CONCLUSION

These results suggest that garenoxacin is a highly effective and safe antimicrobial agent in the treatment of community-acquired upper respiratory infections. Additionally, garenoxacin did not induce the growth of resistant bacteria because of its strong antimicrobial activity.

Authors+Show Affiliations

Department of Otolaryngology-Head and Neck Surgery, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. makoto@med.kanazawa-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22078851

Citation

Ito, Makoto, et al. "Efficacy and Safety of Garenoxacin in the Treatment of Upper Respiratory Tract Infections." Auris, Nasus, Larynx, vol. 39, no. 5, 2012, pp. 512-8.
Ito M, Maruyama Y, Murono S, et al. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. Auris Nasus Larynx. 2012;39(5):512-8.
Ito, M., Maruyama, Y., Murono, S., Wakisaka, N., Kondo, S., Hatano, M., Nakanishi, S., Miwa, T., & Yoshizaki, T. (2012). Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. Auris, Nasus, Larynx, 39(5), 512-8. https://doi.org/10.1016/j.anl.2011.09.004
Ito M, et al. Efficacy and Safety of Garenoxacin in the Treatment of Upper Respiratory Tract Infections. Auris Nasus Larynx. 2012;39(5):512-8. PubMed PMID: 22078851.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. AU - Ito,Makoto, AU - Maruyama,Yumiko, AU - Murono,Shigeyuki, AU - Wakisaka,Naohiro, AU - Kondo,Satoru, AU - Hatano,Miyako, AU - Nakanishi,Sayaka, AU - Miwa,Takaki, AU - Yoshizaki,Tomokazu, Y1 - 2011/11/09/ PY - 2011/07/02/received PY - 2011/08/21/revised PY - 2011/09/03/accepted PY - 2011/11/15/entrez PY - 2011/11/15/pubmed PY - 2012/10/25/medline SP - 512 EP - 8 JF - Auris, nasus, larynx JO - Auris Nasus Larynx VL - 39 IS - 5 N2 - OBJECTIVE: To determine the efficacy and safety of garenoxacin, a new generation of quinolone antimicrobial agent, in the treatment of adult upper respiratory tract infections. METHODS: A total of 113 subjects were enrolled in this study. Garenoxacin (400mg/day) was administered to patients with pharyngolaryngitis, tonsillitis, and otitis media for 5-7 days and to those with sinusitis for 7-10 days. Clinical symptoms and findings were examined and quantitatively evaluated using a scoring system. RESULTS: We found 80 to 100% improvement rate in symptoms and findings for each infection. In addition, we found significant improvement in subjective evaluations from patient questionnaires even in the early stage of the treatment. X-ray examination for acute sinusitis demonstrated that the clinical efficacy was 84% (27/32) and 76% (19/25) patients were already improved within seven days. Among the detected 84 bacteria, 75 (89%) were identified as the major pathogenic bacteria of respiratory tract infections such as Streptococcus pneumoniae (27 strains) and Haemophillus influenzae (14 strains). Garenoxacin administration completely eradicated bacteria in 53 out of 54 cases (98%). There were 8 adverse events (8.3%) including 3 diarrhea cases (3.1%). CONCLUSION: These results suggest that garenoxacin is a highly effective and safe antimicrobial agent in the treatment of community-acquired upper respiratory infections. Additionally, garenoxacin did not induce the growth of resistant bacteria because of its strong antimicrobial activity. SN - 1879-1476 UR - https://www.unboundmedicine.com/medline/citation/22078851/Efficacy_and_safety_of_garenoxacin_in_the_treatment_of_upper_respiratory_tract_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0385-8146(11)00227-6 DB - PRIME DP - Unbound Medicine ER -